Lung-MAP Trial Expands to Include All Patients With NSCLC - OncLive

Vali Papadimitrakopoulou, MD

Vali Papadimitrakopoulou, MD

The Lung Cancer Master Protocol (Lung-MAP), known as the first precision medicine trial in lung cancer supported by the National Cancer Institute (NCI), has expanded to include patients with all types of non–small cell lung cancers (NSCLC), according to SWOG, the organization that manages the trial program.1

The biomarker-driven, umbrella-design trial, which initially launched in 2014, previously enrolled patients with advanced-stage squamous cell lung cancer. It was originally designed to evaluate 4 novel targeted agents and one immunotherapy agent compared with standard-of-care regimens in separate, randomized substudies. Since its inception, Lung-MAP has registered nearly 2000 patients and is offered at more than 650 medical centers and community hospitals in the United States. The stud



http://bit.ly/2RtSpZk

Comments

Popular posts from this blog